Sugi Predict

Sugi Predict / Compounds / SCHEMBL169623

SCHEMBL169623

SCHEMBL169623

Cc1ccc2c(c1)c1c(n2CC(C)(O)c2ccncc2)CCN(C2CC2)C1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH1 P35367 12/20 0.61
▸ HTR6 P50406 10/20 0.49
▸ CNR1 P21554 5/20 0.41
▸ ADRA2A P08913 3/20 0.41
▸ HTR2A P28223 3/20 0.41
▸ HTR2C P28335 3/20 0.41
▸ HTR7 P34969 3/20 0.41
▸ ADRA1A P35348 3/20 0.41
▸ DRD2 P14416 2/20 0.40
▸ GRIN1 Q05586 3/20 0.39
▸ GRIN2A Q12879 3/20 0.39
▸ GRIN2B Q13224 3/20 0.39
▸ GRIN2D O15399 2/20 0.39
▸ GRIN3B O60391 2/20 0.39
▸ GRIN2C Q14957 2/20 0.39
▸ GRIN3A Q8TCU5 2/20 0.39
▸ PTGDR2 Q9Y5Y4 1/20 0.39
▸ BCHE P06276 1/20 0.39
▸ ADRA2B P18089 1/20 0.39
▸ ADRA2C P18825 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13293738 0.93 HRH1 (0.53) HRH1HTR6ADRA2AHTR2AHTR2C
SCHEMBL12819638 0.93 HRH1 (0.52) HRH1HTR6CNR1ADRA2AHTR2A
SCHEMBL169542 0.90 HRH1 (0.52) HRH1HTR6CNR1ADRA2AHTR2A
SCHEMBL17230228 0.87 HRH1 (0.49) HRH1HTR6CNR1ADRA2AHTR2A
SCHEMBL169478 0.86 HRH1 (0.66) HRH1HTR6ADRA2AHTR2AHTR2C
SCHEMBL17590175 0.85 GRIN2B (0.55) HRH1HTR6ADRA2AHTR2AHTR2C
SCHEMBL13293778 0.83 HRH1 (0.45) HRH1HTR6ADRA2AHTR2AHTR2C
SCHEMBL13293774 0.83 HRH1 (0.56) HRH1HTR6ADRA2AHTR2AHTR2C
SCHEMBL169178 0.83 HRH1 (0.49) HRH1HTR6ADRA2AHTR2AHTR2C
SCHEMBL12820295 0.83 HRH1 (0.44) HRH1HTR6CNR1ADRA2AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130190328-A1 PYRIDO[4,3-B]INDOLES AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. (US) 2013-07-25 — — US claimed
US-20120136008-A1 PYRIDO[4,3-B]INDOLES AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. 2012-05-31 — — US claimed
CN-102480955-A Pyrido [4,3-b ] indoles and methods of use MEDIVATION TECHNOLOGIES INC 2012-05-30 — — CN claimed
EP-2424364-A1 PYRIDO [4,3-B] INDOLES AND METHODS OF USE Medivation Technologies, Inc. (US) 2012-03-07 — — EP claimed
WO-2010127177-A1 PYRIDO [4,3-B] INDOLES AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. (US) 2010-11-04 — — WO claimed
US-9550782-B2 Compounds and methods for treating diabetes MEDIVATION TECHNOLOGIES, INC. (US) 2017-01-24 — — US disclosed
US-9550782-B2 Compounds and methods for treating diabetes MEDIVATION TECHNOLOGIES, INC. (US) 2017-01-24 — — US disclosed
US-9527854-B2 Compounds and methods for treatment of hypertension MEDIVATION TECHNOLOGIES, INC. (US) 2016-12-27 — — US disclosed
US-9527854-B2 Compounds and methods for treatment of hypertension MEDIVATION TECHNOLOGIES, INC. (US) 2016-12-27 — — US disclosed
US-9458155-B2 Pyrido[4,3-b]indoles containing rigid moieties MEDIVATION TECHNOLOGIES, INC (US) 2016-10-04 — — US disclosed
US-9458155-B2 Pyrido[4,3-b]indoles containing rigid moieties MEDIVATION TECHNOLOGIES, INC (US) 2016-10-04 — — US disclosed
US-9458155-B2 Pyrido[4,3-b]indoles containing rigid moieties MEDIVATION TECHNOLOGIES, INC (US) 2016-10-04 — — US disclosed
EP-2346332-A1 PYRIDO (4,3-B) INDOLES CONTAINING RIGID MOIETIES Medivation Technologies, Inc. (US) 2011-07-27 — — EP disclosed
WO-2010127177-A1 PYRIDO [4,3-B] INDOLES AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. (US) 2010-11-04 — — WO disclosed
WO-2010127177-A1 PYRIDO [4,3-B] INDOLES AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. (US) 2010-11-04 — — WO disclosed
US-20100216814-A1 PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES MEDIVATION TECHNOLOGIES, INC. 2010-08-26 — — US disclosed
US-20100216814-A1 PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES MEDIVATION TECHNOLOGIES, INC. 2010-08-26 — — US disclosed
US-20100216814-A1 PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES MEDIVATION TECHNOLOGIES, INC. 2010-08-26 — — US disclosed
WO-2010051501-A1 PYRIDO (4,3-B) INDOLES CONTAINING RIGID MOIETIES MEDIVATION TECHNOLOGIES, INC. (US) 2010-05-06 — — WO disclosed
WO-2010051501-A1 PYRIDO (4,3-B) INDOLES CONTAINING RIGID MOIETIES MEDIVATION TECHNOLOGIES, INC. (US) 2010-05-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130190328-A1 PYRIDO[4,3-B]INDOLES AND METHODS OF USE HTR3B, HTR4, HTR2C HRH1 41/4885HTR6 10/4885CNR1 42/4885
US-20120136008-A1 PYRIDO[4,3-B]INDOLES AND METHODS OF USE HTR3B, HTR4, HTR2C HRH1 41/4885HTR6 10/4885CNR1 42/4885
US-20100216814-A1 PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES HTR3B, HTR3D, HTR3A HRH1 537/4885HTR6 13/4885CNR1 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.